{"id":"estradiol-enanthate","rwe":[{"pmid":"40895441","year":"2025","title":"Cross-sex hormone therapy in rats induces sex-specific adaptations of renal function and sodium transporters expression.","finding":"","journal":"Frontiers in physiology","studyType":"Clinical Study"},{"pmid":"39423924","year":"2024","title":"Evaluating changes in body composition, bone mass, and metabolic profile in an animal model undergoing transfeminine hormone therapy and physical exercise.","finding":"","journal":"Clinical nutrition ESPEN","studyType":"Clinical Study"},{"pmid":"39301885","year":"2024","title":"Assessment of parenteral estradiol and dihydroxyprogesterone use among other feminizing regimens for transgender women: insights on satisfaction with breast development from community-based healthcare services.","finding":"","journal":"Annals of medicine","studyType":"Clinical Study"},{"pmid":"35689728","year":"2022","title":"Body, metabolic and renal changes following cross-sex estrogen/progestogen therapy in a rodent model simulating its use by transwomen.","finding":"","journal":"Journal of endocrinological investigation","studyType":"Clinical Study"},{"pmid":"16472564","year":"2006","title":"Comparison of two regimens of a monthly injectable contraceptive containing dihydroxyprogesterone acetophenide and estradiol enanthate.","finding":"","journal":"Contraception","studyType":"Clinical Study"}],"tags":[{"label":"Estrogen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Estrogens","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["estradiol enanthate"],"offLabel":[],"synonyms":["estradiol enanthate"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"moaClass":"Estrogen Receptor Agonists","modality":"Small Molecule","drugClass":"Estrogen","explanation":"Imagine estrogen as a key that unlocks specific doors in your cells. Estradiol enanthate is a copy of that key, allowing it to turn on or off certain cellular processes. This helps regulate various bodily functions, such as growth and development, reproductive processes, and bone health.","oneSentence":"Estradiol enanthate works by binding to estrogen receptors in the body, influencing gene expression and cellular activity.","technicalDetail":"Estradiol enanthate exerts its effects by binding to estrogen receptors (ERα and ERβ), which are transcription factors that regulate gene expression. This binding event triggers a cascade of downstream effects, influencing the expression of target genes involved in various physiological processes."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Estradiol_enanthate","title":"Estradiol enanthate","extract":"Estradiol enanthate, also spelled estradiol enantate and sold under the brand names Perlutal and Topasel among others, is an estrogen medication which is used in hormonal birth control for women. It is formulated in combination with dihydroxyprogesterone acetophenide, a progestin, and is used specifically as a combined injectable contraceptive. Estradiol enanthate is not available for medical use alone. The medication, in combination with DHPA, is given by injection into muscle once a month.","wiki_history":"==History==\nEstradiol enanthate was first described, along with a variety of other estradiol esters, by Karl Junkmann of Schering AG in 1953. The first clinical study of estradiol enanthate and DHPA as a combined injectable contraceptive was conducted in 1964. The combination was marketed by the mid-1970s.","wiki_society_and_culture":"==Society and culture==\n\n===Generic names===\nEstradiol enantate is the British English generic name of the medication and its  and , while estradiol enanthate is its  and American English generic name. Its generic names in other languages are as follows: It has been referred to as estradiol heptanoate.\n\n* EEn 10&nbsp;mg / DHPA 150&nbsp;mg: Acefil, Agurin<sup>†</sup>, Atrimon<sup>†</sup>, Ciclomes, Ciclovar, Ciclovular, Cicnor<sup>†</sup>, Clinomin, Cycloven, Daiva, Damix, Deprans, Deproxone, Exuna, Ginestest, Ginoplan<sup>†</sup>, Gynomes, Horprotal, Listen, Luvonal, Neogestar, Neolutin, Nomagest, Nonestrol, Normagest, Normensil, Novular, Oterol, Ovoginal, Patector, Patectro, Perludil, Perlumes, Perlutal, Perlutale, Perlutan, Perlutin, Perlutin-Unifarma, Permisil, Preg-Less, Pregnolan, Progestrol<sup>†</sup>, Protegin, Proter, Seguralmes, Synovular, Topasel, Unigalen, Uno-Ciclo, and Vagital.\n* EEn 10&nbsp;mg / DHPA 120&nbsp;mg: Anafertin<sup>†</sup>, Patector NF, and Yectames.\n* EEn 5&nbsp;mg / DHPA 75&nbsp;mg: Unalmes and Yectuna.\n* EEn 10&nbsp;mg / DHPA 75&nbsp;mg: Ova Repos<sup>†</sup>.\n* Unsorted: Evitas<sup>†</sup>, Femineo<sup>†</sup>, and Primyfar<sup>†</sup>.\n\nThe combination of EEn 10&nbsp;mg and DHPA 150&nbsp;mg was developed under the developmental brand name Deladroxate, but this brand name was never used commercially. A few different preparations, with varying doses of EEn and DHPA and varying availability, have been introduced.\n\n===Usage===\nEEn/DHPA is the most widely used combined injectable contraceptive in Latin America. It was estimated in 1995 that EEn/DHPA was used as a combined injectable contraceptive in Latin America by at least 1&nbsp;million women. However, combined injectable contraceptives like EEn/DHPA are unlikely to constitute a large proportion of total contraceptive use in the countries in which they are available."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1061","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=estradiol%20enanthate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=estradiol enanthate","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Estradiol_enanthate","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:13:17.501053","biosimilars":[],"competitors":[],"genericName":"estradiol enanthate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07187947","phase":"","title":"Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-07-18","conditions":["Gender Incongruence","Cardiovascular (CV) Risk","Cardiovascular Disease Risk Factor","Cardiovascular Disease Acute","Cardiovascular Health Status","Cardiovascular Disease (CVD)","Cardiovascular Disease Prevention"],"enrollment":500,"completionDate":"2035-12-31"},{"nctId":"NCT03901131","phase":"","title":"PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-08-26","conditions":["Contraceptive"],"enrollment":296,"completionDate":"2022-02-17"},{"nctId":"NCT02038335","phase":"","title":"HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2014-02","conditions":["Contraception","HIV","Immune Cells (Mucosal and Systemic)","Microbiota"],"enrollment":451,"completionDate":"2020-12"},{"nctId":"NCT01862835","phase":"PHASE1","title":"Impact of Estradiol Addback","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-05","conditions":["Normal Healthy Volunteers"],"enrollment":43,"completionDate":"2018-12-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"32888","NDDF":"001265","UNII":"PAP315WZIA","CHEBI":"CHEBI:16469","VANDF":"4017609","INN_ID":"406","RXNORM":"4083","UMLSCUI":"C0059619","ChEMBL_ID":"CHEMBL1697792","KEGG_DRUG":"D04064","DRUGBANK_ID":"DB00783","PDB_CHEM_ID":" EST","PUBCHEM_CID":"21070","SNOMEDCT_US":"126172005","MESH_DESCRIPTOR_UI":"D004958","MESH_SUPPLEMENTAL_RECORD_UI":"C002027"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":40,"therapeuticAreas":["Bone"],"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"40895441","title":"Cross-sex hormone therapy in rats induces sex-specific adaptations of renal function and sodium transporters expression.","journal":"Frontiers in physiology"},{"date":"2024 Dec","pmid":"39423924","title":"Evaluating changes in body composition, bone mass, and metabolic profile in an animal model undergoing transfeminine hormone therapy and physical exercise.","journal":"Clinical nutrition ESPEN"},{"date":"2024 Dec","pmid":"39301885","title":"Assessment of parenteral estradiol and dihydroxyprogesterone use among other feminizing regimens for transgender women: insights on satisfaction with breast development from community-based healthcare services.","journal":"Annals of medicine"},{"date":"2022 Oct","pmid":"35689728","title":"Body, metabolic and renal changes following cross-sex estrogen/progestogen therapy in a rodent model simulating its use by transwomen.","journal":"Journal of endocrinological investigation"},{"date":"2006 Mar","pmid":"16472564","title":"Comparison of two regimens of a monthly injectable contraceptive containing dihydroxyprogesterone acetophenide and estradiol enanthate.","journal":"Contraception"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"estradiol enanthate","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Estradiol enanthate is a small molecule estrogen medication. It is used to treat various conditions, although its specific indications are unknown. As a member of the estrogen class, estradiol enanthate works by mimicking the effects of the naturally occurring hormone estrogen in the body. The commercial status of estradiol enanthate is unclear, and it may be patented or available as a generic medication. Key safety considerations for estradiol enanthate include its potential effects on blood clotting and liver function.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}